Fennec Pharmaceuticals (TSE:FRX) Share Price Passes Below 50 Day Moving Average - What's Next?

Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report) crossed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of C$11.73 and traded as low as C$10.60. Fennec Pharmaceuticals shares last traded at C$10.60, with a volume of 103 shares traded.Get Fennec Pharmaceuticals alerts:Fennec Pharmaceuticals Price PerformanceThe firm has a fifty day moving average of C$11.73 and a 200 day moving average of C$11.73. The company has a current ratio of 7.80, a quick ratio of 10.17 and a debt-to-equity ratio of -620.83. The company has a market capitalization of C$362.02 million, a P/E ratio of -40.77 and a beta of 2.51. Insider Activity at Fennec PharmaceuticalsIn other news, insider Southpoint Capital Advisors Lp sold 20,609 shares of the business's stock in a transaction that occurred on Thursday, October 9th. The shares were sold at an average price of C$12.89, for a total transaction of C$265,650.01. Following the completion of the transaction, the insider directly owned 4,010,100 shares of the company's stock, valued at C$51,690,189. The trade was a 0.51% decrease in their ownership of the stock. Insiders have sold 68,889 shares of company stock valued at $900,406 in the last three months. Insiders own 16.20% of the company's stock. About Fennec Pharmaceuticals (Get Free Report)Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.Featured ArticlesFive stocks we like better than Fennec PharmaceuticalsHow to Profit From Growth Investing Market Momentum: 3 Stocks Poised for Major BreakoutsWhat is the Australian Securities Exchange (ASX) 3 Reasons Casey’s General Stores Will Continue Trending HigherWhat to Know About Investing in Penny StocksGolden Cross Alert: 3 Stocks With Major Upside PotentialThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Fennec Pharmaceuticals Right Now?Before you consider Fennec Pharmaceuticals, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.While Fennec Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here